Angiogenesis-related gene products in preeclampsia

先兆子痫中血管生成相关的基因产物

• 批准号: 7365256
• 负责人: S. Ananth Karumanchi
• 金额: $ 20.54万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7365256
• 关键词: Affect; Angiogenic Factor; Angiogenic Proteins; Animal Model; Binding; Biological Assay; Blood Circulation; Blood Coagulation Disorders; Blood Vessels; Cell Surface Receptors; Clinical; Cytoplasmic Tail; Data; Development; Disease; Edema; Equilibrium; Etiology; Event; Functional disorder; Gene Expression; Gene Expression Regulation; Heterozygote; Hypertension; Hypoxia; Immunohistochemistry; In Vitro; Ischemia; Kidney Failure; Knockout Mice; Lead; Lesion; Messenger RNA; Modeling; Molecular; Morbidity - disease rate; Pathogenesis; Patient currently pregnant; Patients; Placenta; Placental Growth Factor; Placentation; Play; Pre-Eclampsia; Pregnancy; Pregnant Women; Prevention; Production; Properdin; Proteins; Proteinuria; RNA Splicing; Rattus; Receptor Protein-Tyrosine Kinases; Reporting; Research Personnel; Rodent; Role; Serum; Symptoms; Testing; Therapeutic; Time; Transcriptional Activation; Up-Regulation; Variant; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors; Week; Woman; angiogenesis; antiangiogenesis therapy; cytotrophoblast; falls; fetal; glomerular filtration; in vivo; in vivo Bioassay; insight; mortality; normotensive; novel; novel therapeutics; podocyte; prevent; programs; research study; response

DESCRIPTION (provided by applicant): Preeclampsia (PE) is a disease, which affects 5-7% of all pregnancies and is characterized by severe hypertension, proteinuria and edema. Endothelial dysfunction plays an important role in the pathogenesis of this disorder; however, the etiology and mechanisms are still unknown. We recently found that placentas from preeclamptic patients produce an excess of a naturally occurring anti-angiogenic protein, sFIt-1 (soluble fms-like tyrosine kinase-1), resulting in increased serum levels in patients with PE as compared to normotensive pregnant women. Fit-1 is one of the tyrosine kinase receptors for vascular endothelial growth factor (VEGF) and placental growth factor (PIGF). sFIt-1, a secreted splice variant of Fit-1 (lacking the transmembrane and cytoplasmic domains) potently antagonizes VEGF and PIGF, by preventing their binding to the cell-surface receptor. Moreover, we have found that the ratio of anti-angiogenic (sFIt-1) to pro-angiogenic (VEGF + PIGF) proteins in the maternal bloodstream at the time of delivery is substantially elevated in preeclamptic women as compared with control pregnant women. In vitro, preeclamptic serum but not normal pregnant serum induces endothelial dysfunction due to excess sFIt-1, which can be rescued by exogenous VEGF and PIGF. Finally, we have preliminary data that administration of exogenous sFIt-1 to pregnant rats induces hypertension, heavy proteinuria and glomerular endotheliosis, the classic lesion of PE. We therefore hypothesize that alteration in the angiogenic balance due to excess sFLt-1 results in the development of PE. This proposal aims to clarify the role of sFIt-1 and altered angiogenic balance in the pathogenesis of PE. We will first characterize our sFIt-1 induced animal model for PE and will test several therapeutic compounds in an attempt to find new treatment options for patients with PE. We will then elucidate the mechanisms of systemic vascular dysfunction and placental cytotrophoblast dysfunction induced by excess sFIt-1 and altered angiogenic balance using both in vitro and in vivo experiments. Finally, we will focus on studying the transcriptional and post-transcriptional regulatory mechanisms of sFIt-1 production by placental cytotrophoblasts. These focused studies will form the beginnings of a framework for understanding the role of angiogenesis-related gene products in pathogenesis of PE and for exploring novel avenues for the treatment of PE.

描述（由申请人提供）：先兆子痫（PE）是一种影响所有妊娠的 5-7% 的疾病，其特征是严重高血压、蛋白尿和水肿。内皮功能障碍在该疾病的发病机制中起着重要作用。然而，其病因和机制仍不清楚。我们最近发现先兆子痫患者的胎盘产生过量的天然存在的抗血管生成蛋白 sFIt-1（可溶性 fms 样酪氨酸激酶-1），导致 PE 患者的血清水平与血压正常的孕妇相比升高。 Fit-1 是血管内皮生长因子 (VEGF) 和胎盘生长因子 (PIGF) 的酪氨酸激酶受体之一。 sFIt-1 是 Fit-1 的一种分泌性剪接变体（缺乏跨膜和细胞质结构域），通过阻止 VEGF 和 PIGF 与细胞表面受体结合，有效拮抗 VEGF 和 PIGF。此外，我们发现，与对照孕妇相比，先兆子痫女性在分娩时母体血液中抗血管生成（sFIt-1）与促血管生成（VEGF + PIGF）蛋白的比率显着升高。在体外，先兆子痫血清而非正常妊娠血清会因过量的 sFIt-1 引起内皮功能障碍，而外源性 VEGF 和 PIGF 可以挽救这种功能障碍。最后，我们有初步数据表明，给怀孕大鼠注射外源性sFIt-1会诱发高血压、大量蛋白尿和肾小球内皮增生，这是PE的典型病变。因此，我们假设 sFLt-1 过量导致血管生成平衡的改变导致 PE 的发生。该提案旨在阐明 sFIt-1 和改变的血管生成平衡在 PE 发病机制中的作用。我们将首先表征 sFIt-1 诱导的 PE 动物模型，并将测试几种治疗化合物，试图为 PE 患者找到新的治疗选择。然后，我们将通过体外和体内实验阐明过量 sFIt-1 和血管生成平衡改变引起的全身血管功能障碍和胎盘细胞滋养层功能障碍的机制。最后，我们将重点研究胎盘细胞滋养层产生sFIt-1的转录和转录后调控机制。这些重点研究将为了解血管生成相关基因产物在肺栓塞发病机制中的作用和探索治疗肺栓塞的新途径奠定基础。